Your browser doesn't support javascript.
loading
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Luoma, Adrienne M; Suo, Shengbao; Williams, Hannah L; Sharova, Tatyana; Sullivan, Keri; Manos, Michael; Bowling, Peter; Hodi, F Stephen; Rahma, Osama; Sullivan, Ryan J; Boland, Genevieve M; Nowak, Jonathan A; Dougan, Stephanie K; Dougan, Michael; Yuan, Guo-Cheng; Wucherpfennig, Kai W.
Afiliação
  • Luoma AM; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.
  • Suo S; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
  • Williams HL; Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA.
  • Sharova T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Sullivan K; Division of Gastroenterology and Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA.
  • Manos M; Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Bowling P; Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Rahma O; Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA; Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
  • Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Boland GM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Nowak JA; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA.
  • Dougan SK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.
  • Dougan M; Division of Gastroenterology and Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA. Electronic address: mldougan@partners.org.
  • Yuan GC; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA.
  • Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA; Department of Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: k
Cell ; 182(3): 655-671.e22, 2020 08 06.
Article em En | MEDLINE | ID: mdl-32603654
ABSTRACT
Checkpoint blockade with antibodies specific for the PD-1 and CTLA-4 inhibitory receptors can induce durable responses in a wide range of human cancers. However, the immunological mechanisms responsible for severe inflammatory side effects remain poorly understood. Here we report a comprehensive single-cell analysis of immune cell populations in colitis, a common and severe side effect of checkpoint blockade. We observed a striking accumulation of CD8 T cells with highly cytotoxic and proliferative states and no evidence of regulatory T cell depletion. T cell receptor (TCR) sequence analysis demonstrated that a substantial fraction of colitis-associated CD8 T cells originated from tissue-resident populations, explaining the frequently early onset of colitis symptoms following treatment initiation. Our analysis also identified cytokines, chemokines, and surface receptors that could serve as therapeutic targets for colitis and potentially other inflammatory side effects of checkpoint blockade.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite / Linfócitos T CD8-Positivos / Receptores de Quimiocinas / Células Mieloides / Antígeno CTLA-4 / Inibidores de Checkpoint Imunológico / Imunoterapia Idioma: En Revista: Cell Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite / Linfócitos T CD8-Positivos / Receptores de Quimiocinas / Células Mieloides / Antígeno CTLA-4 / Inibidores de Checkpoint Imunológico / Imunoterapia Idioma: En Revista: Cell Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos